Dengue tetravalent vaccine, live

DB14764ApprovedInvestigationalVaccines

The dengue tetravalent vaccine (Qdenga) is indicated for preventing dengue disease in individuals aged 4 years and older.

Primary indication
The dengue tetravalent vaccine (Qdenga) is indicated for preventing dengue disease in individuals aged 4 years and older.Curator reviewed · 1 structured indication
Also known as
Dengue tetravalent vaccine (live, attenuated) · Dengue vaccine · Qdenga

What you can answer from here — as of July 19, 2025

289Drug interactionsStructured to mechanism, not free text
Sign in
29Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
2ContraindicationsEach with its own population and attribute set
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which other approved drugs treat the same conditions as Dengue tetravalent vaccine, live, and which companies have late-stage candidates in those indications?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In